Stock JANX JANUX THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Janux Therapeutics, Inc.

Equities

JANX

US47103J1051

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-06 pm EDT 		5-day change 1st Jan Change
42.59 USD -8.94% Intraday chart for Janux Therapeutics, Inc. -10.53% +296.92%
Jun. 06 Janux Therapeutics Insider Sold Shares Worth $45,043,975, According to a Recent SEC Filing MT
Jun. 06 Janux Therapeutics Insider Sold Shares Worth $82,125,000, According to a Recent SEC Filing MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Janux Therapeutics Insider Sold Shares Worth $45,043,975, According to a Recent SEC Filing
MT
Janux Therapeutics Insider Sold Shares Worth $82,125,000, According to a Recent SEC Filing
MT
Scotiabank Starts Janux Therapeutics With Sector Perform Rating
MT
Certain Pre Funded Warrants of Janux Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 30-MAY-2024.
CI
Certain Stock Options of Janux Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 30-MAY-2024.
CI
Certain Common Stock of Janux Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 30-MAY-2024.
CI
Wedbush Raises Janux Therapeutics' PT to $74 From $53, Keeps Outperform Rating
MT
Janux Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Janux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
BU
JonesTrading Starts Janux Therapeutics With Buy Rating, $70 Price Target
MT
Sector Update: Health Care Stocks Slipping Late Afternoon
MT
Sector Update: Health Care
MT
Janux Therapeutics Said to be Considering Sale
MT
Janux Therapeutics Considering Options, Including Sale, Bloomberg Reports
MT
Janux Therapeutics Reportedly Weighs Possible Sale
CI
BTIG Starts Janux Therapeutics With Buy Rating, $62 Price Target
MT
Cantor Fitzgerald Starts Janux Therapeutics With Overweight Rating, $100 Price Target
MT
H.C. Wainwright Adjusts Price Target on Janux Therapeutics to $50 From $35, Keeps Buy Rating
MT
Janux Therapeutics Q4 Net Loss Narrows, Revenue Decreases
MT
Janux Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. JANX Stock
  4. News Janux Therapeutics, Inc.